176 related articles for article (PubMed ID: 34893510)
21. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
Keats JJ; Maxwell CA; Taylor BJ; Hendzel MJ; Chesi M; Bergsagel PL; Larratt LM; Mant MJ; Reiman T; Belch AR; Pilarski LM
Blood; 2005 May; 105(10):4060-9. PubMed ID: 15677557
[TBL] [Abstract][Full Text] [Related]
23. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
24. Histone H3K4me1 strongly activates the DNase I hypersensitive sites in super-enhancers than those in typical enhancers.
Kang Y; Kang J; Kim A
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34195788
[TBL] [Abstract][Full Text] [Related]
25. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
[TBL] [Abstract][Full Text] [Related]
26. Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
Wong RWJ; Ngoc PCT; Leong WZ; Yam AWY; Zhang T; Asamitsu K; Iida S; Okamoto T; Ueda R; Gray NS; Ishida T; Sanda T
Blood; 2017 Nov; 130(21):2326-2338. PubMed ID: 28978570
[TBL] [Abstract][Full Text] [Related]
27. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Choudhury SR; Ashby C; Tytarenko R; Bauer M; Wang Y; Deshpande S; Den J; Schinke C; Zangari M; Thanendrarajan S; Davies FE; van Rhee F; Morgan GJ; Walker BA
J Hematol Oncol; 2020 Aug; 13(1):108. PubMed ID: 32762714
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of HJURP inhibits non-small cell lung cancer cell proliferation, migration, and invasion by repressing Wnt/β-catenin signaling.
Wei Y; Ouyang GL; Yao WX; Zhu YJ; Li X; Huang LX; Yang XW; Jiang WJ
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3847-3856. PubMed ID: 31115012
[TBL] [Abstract][Full Text] [Related]
30. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
31. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
[TBL] [Abstract][Full Text] [Related]
32. EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
Nishiyama D; Chinen Y; Isa R; Fujibayashi Y; Kuwahara-Ota S; Yamaguchi J; Takimoto-Shimomura T; Matsumura-Kimoto Y; Tsukamoto T; Shimura Y; Kobayashi T; Horiike S; Taniwaki M; Handa H; Kuroda J
Int J Hematol; 2021 Mar; 113(3):381-394. PubMed ID: 33095415
[TBL] [Abstract][Full Text] [Related]
33. Long Noncoding RNA LUCAT1 Promotes Multiple Myeloma Cell Growth by Regulating the TGF-β Signaling Pathway.
Liu Z; Gao H; Peng Q; Yang Y
Technol Cancer Res Treat; 2020; 19():1533033820945770. PubMed ID: 32812490
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
Tatetsu H; Ueno S; Hata H; Yamada Y; Takeya M; Mitsuya H; Tenen DG; Okuno Y
Cancer Res; 2007 Jun; 67(11):5328-36. PubMed ID: 17545613
[TBL] [Abstract][Full Text] [Related]
35. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
[TBL] [Abstract][Full Text] [Related]
36. C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.
Pal R; Janz M; Galson DL; Gries M; Li S; Jöhrens K; Anagnostopoulos I; Dörken B; Mapara MY; Borghesi L; Kardava L; Roodman GD; Milcarek C; Lentzsch S
Blood; 2009 Oct; 114(18):3890-8. PubMed ID: 19717648
[TBL] [Abstract][Full Text] [Related]
37. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Lovén J; Hoke HA; Lin CY; Lau A; Orlando DA; Vakoc CR; Bradner JE; Lee TI; Young RA
Cell; 2013 Apr; 153(2):320-34. PubMed ID: 23582323
[TBL] [Abstract][Full Text] [Related]
39. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.
Alaterre E; Ovejero S; Herviou L; de Boussac H; Papadopoulos G; Kulis M; Boireau S; Robert N; Requirand G; Bruyer A; Cartron G; Vincent L; Martinez AM; Martin-Subero JI; Cavalli G; Moreaux J
Theranostics; 2022; 12(4):1715-1729. PubMed ID: 35198065
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]